Latest Breaking News On - Professor behnam badie - Page 1 : comparemela.com

Chimeric Therapeutics Ltd (ASX:CHM) has received encouraging data from the second dose cohort of its CLTX CAR T Phase 1 dose escalation study for patients.

United statesChimeric therapeutics ltdProfessor behnam badie